Signals are just the beginning. Fundz delivers what’s next.
Fundz reads more than a dozen live signals on every company, scores each one against your exact market, and weaves in your own network. Each morning you get the few worth your time: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
ADC Therapeutics SA secures $86.6 million in Private Equity financing, with participation from Bain Capital Life Sciences and existing investors. This strategic move aims to extend the company's cash runway into 2029.
PUBLIC · ADCTOct 08, 2026
Amount Raised
$86.6 Million
Round Type
Private Equity
LausanneBiotechnologyHealth CareTherapeutics
Investors
Nantahala CapitalTcgxRedmileBain Capital Life Sciences
Description
ADC Therapeutics SA has announced a strategic financial restructuring, which includes a $86.6 million private placement involving both new and existing investors. This financing effort is intended to enhance the company’s capital structure and extend its cash runway. The deal includes participation from Bain Capital Life Sciences among others. The restructuring aims to maximize shareholder value and reduce leverage.
Company Information
Company
ADC Therapeutics
Location
Lausanne, Vaud, Switzerland
About
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
Fundz sees it the moment ADC Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.